Wedge Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Wedge Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-100,505	Closed	-$434K	–	515
2023 Q3	$434K	Sell	100,505 -155,058	-61%	-$862K	0.01%	434
2023 Q2	$1.68M	Buy	255,563 +236,209	+1,220%	+$1.51M	0.03%	384
2023 Q1	$131K	Buy	19,354 +8,350	+76%	+$58.7K	﹤0.01%	421
2022 Q4	$81K	Buy	+11,004	New	+$107K	﹤0.01%	415
2022 Q3	–	Sell	-11,206	Closed	-$122K	–	432
2022 Q2	$122K	Buy	11,206 +902	+9%	+$9.35K	﹤0.01%	401
2022 Q1	$117K	Buy	+10,304	New	+$135K	﹤0.01%	416
2021 Q1	–	Sell	-10,910	Closed	-$143K	–	591
2020 Q4	$143K	Buy	+10,910	New	+$131K	﹤0.01%	549

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Wedge Capital Management's VNDA Position: Q4 2023 in Review

Wedge Capital Management sold out of Vanda Pharmaceuticals (VNDA) in Q4 2023, closing a stake of 100,505 shares — an estimated $434K sold.

Wedge Capital Management first reported a position in VNDA in Q4 2020 and held it in 7 quarters. The position peaked at $1.68M in Q2 2023. 157 funds tracked by Wall St. Rank hold VNDA as of Q4 2023.

Wedge Capital Management reported no remaining Vanda Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Wedge Capital Management sold 100,505 Vanda Pharmaceuticals shares in Q4 2023, an estimated $434K.
Wedge Capital Management first reported a position in Vanda Pharmaceuticals in Q4 2020 and held it in 7 quarters.
Wedge Capital Management's Vanda Pharmaceuticals position peaked at $1.68M in Q2 2023.
157 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2023.

Based on Wedge Capital Management's 13F filing for Q4 2023, filed 1 Feb 2024.